Every year, about one million new cases of colon cancer are diagnosed worldwide. About 150,000 new cases are detected each year in the United States. Over a lifetime, about 1 in 19 people develop colon cancer and nearly 50,000 people are expected to die from it in the U.S. this year. According to the American Cancer Society, colon cancer is the third leading cause of cancer-related death in the U.S., accounting for about 10 percent of all cancer deaths.
CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.
A team of researchers at Sweden’s Karolinska Institutet studied how specific immune cells known as innate lymphoid cells (ILCs), which play a role in inflammatory bowel disease (IBD), evolve into mature cells.
Mutations in the APC gene cause the production of intestinal polyps in persons suffering from familial adenomatous polyposis, a genetic disease that predisposes them to colon cancer.
There are many proteins involved in the spread of cancer. However, some of them are notably difficult to observe in patient tissue samples.
According to research published in eLife, researchers have developed a pipeline for detecting, prioritizing, and testing potential tumor antigens for the rapid development of cancer vaccines.
Scientists develop a new fluorescent label that provides a sharper image of how DNA architecture is disturbed in cancer cells.
A recently published paper in the journal Molecular Cancer by the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA Research Professor and Genetics Chairman at the University of Barcelona, shows that transfer RNAs for certain amino acids are altered at the epigenetic level in some types of cancer, expressing it in an exaggerated manner in some cases and being deficient in others.
New studies emerge daily on the effect of the human microbiome on human health: colon cancer, ulcers, and cognitive conditions such as Alzheimer's disease have been associated with the communities of microbes that live in our bodies.
New clinical research indicates that a widely used food additive, carboxymethylcellulose, alters the intestinal environment of healthy persons, perturbing levels of beneficial bacteria and nutrients.
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors.
A new study has discovered a two-arm molecule that can effectively deplete cancer-protecting cells within tumors.
Cell growth requires new proteins and the same applies to cancer cells. Scientists analyzed the protein eIF4A3 and its role in the growth of cancer cells.
Scientists and faculty of Vanderbilt University are in search of the “Achilles’ heel” of cancer cells that survive initial chemotherapy.
Most of the tests that doctors use to diagnose cancer -- such as mammography, colonoscopy, and CT scans -- are based on imaging. More recently, researchers have also developed molecular diagnostics that can detect specific cancer-associated molecules that circulate in bodily fluids like blood or urine.
The Families SHARE workbook was developed by researchers at the NHGRI, which is part of the National Institutes of Health (NIH).
For decades, physicians and dieticians have urged people to limit their intake of high fat foods, citing links to poor health outcomes and some of the leading causes of death in the U.S., such as diabetes, heart disease and cancer.
A class of drug called monoamine oxidase inhibitors is commonly prescribed to treat depression; the medications work by boosting levels of serotonin, the brain's "happiness hormone."
What makes cancer cells different from ordinary cells in our bodies? Can these differences be used to strike at them and paralyze their activity?
A microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers, according to new research from investigators with the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination - of irinotecan, cetuximab, and vemurafenib - is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.